MelissaHe Ph.D.

Law Clerk

Washington + 1.202.879.3427

Dr. Melissa He prosecutes patents and manages patent portfolios worldwide in the areas of pharmaceuticals, biotechnology, and chemistry. She provides clients with a broad range of services, including U.S. and foreign patent portfolio development and management, due diligence investigation, patentability and validity assessments, freedom-to-operate analysis, and patent strategy counseling.

Melissa also has experience in patent litigation and post-grant proceedings, including inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has worked on drafting declarations, expert reports, and preparing experts for depositions.

Prior to joining Jones Day, Melissa was an IP and life sciences analyst for more than three years at an international law firm and worked as a scientist for more than 10 years. During her post-doctoral fellowship in the National Institutes of Health (NIH) and scientific education, she researched discovery (or repurposing) and development of pharmaceutical candidates treating infectious diseases. Melissa is a co-inventor of patent applications involving small-molecule drug discovery. She is also the first author of several peer-reviewed scientific publications in journals including Science Translational Medicine and Journal of Medicinal Chemistry. Her publications have been featured in "Research Highlights" in Nature Reviews Drug Discovery and Nature Reviews Gastroenterology & Hematology and selected for American Chemical Society's ACS Editors' Choice. Her research also has been spotlighted in NIH Research Matters, Yahoo News, and TIME Health.


  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.